The state of Pennsylvania currently has 17 active clinical trials seeking participants for Ulcerative Colitis research studies. These trials are conducted in various cities, including Philadelphia, Pittsburgh, Hershey and Allentown.
Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC). Participants will be randomized to receive 1 of 3 efavaleukin alfa doses or placebo during a 12-week induction period. Participants who complete the 12-week induction period will have the option to enter an exploratory long-term treatment period for up to 40 weeks (total of up to 52 weeks of treatment) if, in... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/27/2024
Locations: Guthrie Robert Packer Hospital, Sayre, Pennsylvania
Conditions: Ulcerative Colitis
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania +1 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and effective ABBV-668 is in treating adult participants with UC. Adverse events and change in disease activity will be assessed. ABBV-668 is an investigational drug being developed for the treatment of moderate to severe UC. Approximately 40 adult participants diagnosed with UC will be enrolled in approx... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: University of Pennsylvania /ID# 250012, Philadelphia, Pennsylvania +2 locations
Conditions: Ulcerative Colitis
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
Recruiting
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/07/2024
Locations: Care Access - Pottsville, Pottsville, Pennsylvania +1 locations
Conditions: Ulcerative Colitis
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Recruiting
The study is an extension of two parent studies (MLN0002-3024 [NCT04779307] and MLN0002-3025 [NCT04779320]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.
Gender:
All
Ages:
2 years and above
Trial Updated:
03/05/2024
Locations: Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Ulcerative Colitis, Crohn's Disease
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
Recruiting
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of the US or EU, patients having had inadequate response or intolerance to oral or IV corticosteroids or azathioprine or 6-mercaptopurine or TNFi will be enrolled. All eligible participants will initially receive open label tofacitinib... Read More
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
03/04/2024
Locations: Buerger Center for Advanced Pediatric Care, Philadelphia, Pennsylvania +2 locations
Conditions: Ulcerative Colitis
Nicotinamide Riboside in Ulcerative Colitis
Recruiting
This is a randomized, double-blind pilot study of Nicotinamide Riboside (NR) in Pediatric-onset Ulcerative Colitis (UC).
Gender:
All
Ages:
18 years and below
Trial Updated:
03/02/2024
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Ulcerative Colitis
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
Recruiting
The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled parent studies including but not limited to: (APD334-301 [NCT03945188] or APD334-302 [NCT03996369] or APD334-210 [NCT04607837]).
Gender:
All
Ages:
Between 16 years and 80 years
Trial Updated:
03/01/2024
Locations: Great Lakes Medical Research, LLC, Camp Hill, Pennsylvania +4 locations
Conditions: Ulcerative Colitis
Hyperbaric Oxygen Therapy for Ulcerative Colitis
Recruiting
Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis (UC). Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen under increased atmospheric pressure to increase tissue oxygenation. Two small prospective randomized controlled trials have demonstrated that the delivery of HBOT to UC patients hospitalized for acute moderate to severe flares results in improved remission rates and avoidance of in-hospital progression to biologics, small mole... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
02/29/2024
Locations: Allegheny Health, Pittsburgh, Pennsylvania +1 locations
Conditions: Ulcerative Colitis
Fecal Microbiome Transplant
Recruiting
Fecal Microbiota Transplant (FMT) in pediatric patients with recurrent C. Difficile with or without Inflammatory Bowel Disease (IBD) The aims of this study are to determine the safety and efficacy of FMT treatment in pediatric patients with recurrent or moderate to severe C. Difficile without (through an observational study) and with (through a clinical trial) Inflammatory Bowel Disease and to determine the effect of FMT on the gut microbiota through the use of 454 pyrosequencing before and aft... Read More
Gender:
All
Ages:
Between 3 years and 21 years
Trial Updated:
02/13/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Clostridium Difficile, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
Recruiting
The study will compare the effectiveness of Bezlotoxumab in individuals with active C. diff ( Clostridium difficile) infection who are diagnosed with Inflammatory Bowel Disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, C. Diff. Infections
Phase 2a To Evaluate PL-8177 in Subjects With Active Ulcerative Colitis (UC)
Recruiting
The purpose of this study is to compare PL8177 (a melanocortin receptor agonist) to placebo (in a 3:1 ratio-meaning that for every 3 people that get the active drug, one will receive placebo). The study treatment will be for 8 weeks. The study will measure safety and the body's ability to handle PL8177 and look at the improvement and healing of the intestine after 8 weeks of treatment. The study will include adult males and nonpregnant, nonlactating females with acute Ulcerative Colitis (UC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/08/2024
Locations: UPMC Presbyterian, Pittsburgh, Pennsylvania
Conditions: Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative, Ulcerative Colitis Flare